11.09.15Back to News

Paradigm Leadership and TCGA Publish Study on Comprehensive Genomic Analysis of Primary Prostate Tumors in Cell


Paradigm Leadership played key leadership roles in a recently published study analyzing genomic changes in primary prostate tumors that has provided the most comprehensive and integrated view of gene changes for prostate cancer to date. In this National Institute of Health-funded, The Cancer Genome Atlas (TCGA) project, Paradigm leveraged experience and expertise from The International Genomics Consortium and our innovative Expression Project for Oncology (expO) to define and build the Biospecimen Core Resource and the Tissue Source Site Network.

TCGA Research Network examined more than 300 primary prostate cancers. The analyses are reported online in the journal Cell and cite Paradigm Leadership among contributing authors to the article “The Molecular Taxonomy of Primary Prostate Cancer”.

The TCGA analysis leveraged various analytic platforms including Next-Generation Sequencing (NGS) to identify significant copy-number alterations, mutations, gene fusions, mRNA expression levels, protein expression and methylation.

We report that comprehensive molecular analysis demonstrated that 74% of the tumors fell into one of seven subtypes defined by particular gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1).

Twenty-five percent of the prostate cancers analyzed had a potentially actionable lesion in the PI3K or MAPK signaling pathways, and genes related to DNA repair were inactivated in 19% of tumors analyzed.

Paradigm continues to partner and author important manuscripts with exceptional biopharma and research organizations in order to understand as early as possible the drivers of ongogenesis. Monitoring the primary literature and clinical trials in progress allows us to update the PCDx assay in near real time to stay current with molecular pathway and drug treatment associations.

“Paradigm leadership are very proud to participate in this world-class project that we believe will translate into more precise diagnostics and treatments for future cancer patients,” said Dr. Robert Penny, CEO of IGC, serving as Principal Investigator of the Biospecimen Core Resource and Tissue Source Site network.

See Full Article

# # #


Paradigm is a non-profit molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit www.paradigmdx.com

Also, follow us on Twitter @Paradigm_DX


Start getting better results, faster.

Order PCDx